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AMD served as controls. The primary endpoint was the 
change in EF assessed by flow-mediated dilatation (FMD) af-
ter 2 months of treatment with VEGF inhibitors in patients 
with AMD compared to patients with dry AMD. FMD was as-
sessed with B-mode high-resolution ultrasonography of the 
left brachial artery.  Results: 24 patients with neovascular 
AMD and 26 patients with dry ADM were included in the 
trial. Treatment with VEGF inhibitors did not significantly 
change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9% after 8 weeks,  p = 
0.07, and to 5.1 ± 2.0% after 1 year;  p = 0.93 vs. baseline, re-
spectively).  Conclusions: EF did not significantly differ be-
tween patients with neovascular AMD treated with intra-
vitreal VEGF inhibition and patients with dry AMD. 
 © 2017 S. Karger AG, Basel 
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 Abstract 
 Objective: To determine whether intraocular treatment with 
vascular endothelial growth factor (VEGF) inhibitors change 
systemic endothelial function (EF) in patients with neovas-
cular age-related macular degeneration (AMD).  Methods: In 
this prospective, randomized, 2-center, double-masked con-
trolled interventional trial, patients with neovascular and dry 
AMD were enrolled. Eligible neovascular AMD patients re-
ceived 2 intravitreal loading doses of either ranibizumab 0.5 
mg or bevacizumab 1.25 mg at 4-week intervals and were 
subsequently followed every 4 weeks and treated according 
to a pro re nata regime for up to 1 year. Patients with dry 
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 Introduction 
 Over the last decade anti-vascular endothelial growth 
factor (VEGF) therapy has become the gold standard in 
the treatment of neovascular age-related macular degen-
eration (AMD). Recently, multiple controlled clinical tri-
als comparing the 2 most commonly used VEGF inhibi-
tors bevacizumab and ranibizumab have shown similar 
functional results in patients with neovascular AMD  [1–
4] . However, systemic safety of intravitreal anti-VEGF 
therapy remains controversial. None of the prospective 
clinical trials were designed to evaluate rare systemic 
events, and even meta-analyses have insufficient power to 
conclusively exclude anti-VEGF therapy-induced sys-
temic adverse effects  [5] . Importantly, none of these trials 
specifically addressed cardiovascular safety, which is of 
particular concern, as patients with AMD are predomi-
nantly elderly and present with a number of cardiovascu-
lar risk factors and/or established cardio- and cerebrovas-
cular disease  [6–9] .
 Intraocular VEGF antagonism constitutes a break-
through in neovascular AMD management by reducing 
AMD-related loss of visual acuity  [10] . However, an 
interdisciplinary discussion brings various aspects of 
VEGF inhibition into focus. In view of the well-estab-
lished cardioprotective effects of VEGF and its down-
stream denominator nitric oxide (NO), the beneficial lo-
cal effects of VEGF inhibition on choroidal neovascular-
ization (CNV) may come at the cost of systemic side 
effects related to VEGF inhibition such as increased 
thromboembolic events  [11] . Several clinical studies have 
indicated that serum and plasma VEGF levels are reduced 
following intravitreal anti-VEGF therapy  [12, 13] . This 
reduction might be dependent on the drug and treatment 
strategy. It is, however, unclear to which extent the reduc-
tion in unbound VEGF has a relevant effect on vascular 
endothelial function (EF). One of the most established 
and sensitive markers of EF in patients, an independent 
predictor of cardiovascular events, is the measurement of 
flow-mediated dilatation (FMD)  [14] . As impaired bio-
availability of NO within the vascular wall is considered 
a hallmark of endothelial dysfunction, and endothelial 
NO release is the downstream denominator of VEGF, 
there is concern that anti-VEGF therapy decreases NO 
and thus impairs EF  [11, 15, 16] .
 Thus, this prospective, 2-center, randomized, double-
masked, controlled, interventional trial was designed to 
investigate both the local effects of intravitreal VEGF an-
tagonism on CNV and macular edema, as assessed by 
 fluorescein angiography (FA), optical coherence tomog-
raphy (OCT), and best corrected visual acuity (BCVA), 
and, at the same time, systemic effects on EF, vascular 
compliance, and 24-h blood pressure in patients with 
neovascular (wet) AMD, receiving anti-VEGF therapy 
compared to patients with dry AMD without anti-VEGF 
therapy.
 Methods 
 Study Population 
 In this prospective, 2-center, randomized, double-masked, 
controlled, interventional trial, patients with wet (neovascular) 
AMD (documented by OCT and FA) suitable for intravitreal anti-
VEGF therapy were recruited at the Department of Ophthalmol-
ogy, University Hospital Zurich, and the Department of Ophthal-
mology, Stadtspital Triemli Zurich (both in Switzerland). Patients 
were on stable medication for general conditions for  ≥ 1 month 
and were >50 years of age, and gave written informed consent. In-
clusion criteria for the control group were the same as for the anti-
VEGF treatment group except for the diagnosis of dry AMD, 
which was defined as at least category 2 according to the Age-Re-
lated-Eye-Disease-Study (AREDS)  [17] in both eyes and no evi-
dence of neovascularization in either eye.
 Exclusion criteria were acute myocardial infarction, unstable 
angina, stroke, or a coronary intervention/revascularization pro-
cedure  ≤ 3 months prior to study entry, uncontrolled symptom-
atic congestive heart failure (New York Heart Association func-
tional class >II)  ≤ 4 weeks prior to study entry, renal failure (cre-
atinine clearance using the MDRD formula  [18] <50 mL/min), 
ventricular tachyarrhythmia, poorly controlled blood pressure de-
spite adequate therapy ( ≥ 160/100 mm Hg), symptomatic hypoten-
sion, chronic use of long-acting nitrates, smoking (>5 cigarettes/
day), diabetes mellitus, dyslipidemia (LDL cholesterol >4.5 
mmol/L), liver disease (ALT or AST >3× ULN), alcohol or illicit 
substance abuse, known hypersensitivity to the active study drugs 
or to any of the excipients, active or suspected ocular or periocular 
infections, active severe intraocular inflammation, malignancy 
(unless healed or remission >5 years), systemic inflammatory dis-
eases (e.g., rheumatoid arthritis or Crohn disease) and the partici-
pation in another study within 1 month prior to study entry.
 Study Design and Protocol 
 According to the study protocol, 50 patients with neovascular 
AMD who were scheduled for treatment (2 initial injections at 
4-week intervals) with ranibizumab (Novartis Pharma Schweiz 
AG, Rotkreuz, Switzerland) or bevacizumab (Roche Pharma 
 Schweiz AG, Reinach, Switzerland) were scheduled to be included 
in the study. Patients were seen every 4 weeks, and retreatment was 
conducted – following the two loading doses – according to the pro 
re nata (PRN) regimen of the 2nd year in the PrONTO study  [19] . 
Moreover, 25 control subjects with dry AMD were scheduled to be 
recruited at the same centers. This design was chosen because pla-
cebo injections in patients with wet AMD were considered un-
ethical due to the proven marked improvement in visual acuity 
following intravitreal VEGF antagonism. The primary endpoint 
was the impact of ranibizumab or bevacizumab on endothelium-
dependent and -independent vasodilatation after 8 weeks of treat-
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ment in patients with wet AMD compared to a control group of 
untreated patients with dry AMD. Prespecified secondary end-
points were changes in vascular compliance, mean BCVA and 
CNV activity (as determined by central retinal thickness using 
OCT), and changes in systemic inflammatory markers, surrogates 
for oxidative stress, and mean systolic and diastolic 24-h blood 
pressure. Prespecified safety endpoints were incidence of any sys-
temic and ocular adverse events, including death, thromboembol-
ic events, and changes in safety laboratory assessments and vital 
signs versus baseline. On visit 1 (day 0), after obtaining informed 
consent, medical history was taken, physical examinations, e.g., 
FA, OCT, BCVA, complete ophthalmic examination, vascular 
compliance, EF, and 24-h blood pressure, were performed, and 
blood samples were drawn for systemic analyses. After completing 
the examination, the study drug (0.5 mg ranibizumab or 1.25 mg 
bevacizumab) was administered according to randomization (vis-
it 1, day 0); 24 h after the study drug administration, a second as-
sessment of EF and vascular compliance was performed, and blood 
samples for systemic analyses were again drawn to assess imme-
diate effects (visit 2, day 1). After 4 weeks, the study drug was re-
Visit 1 + 2
- BS, VC, CAP
- VA, OCT, FA
- EF
- 24-h BP
- Study drug
 (only V1)
Visit 3
- Ophthalmol.
 Examination
- VA, OCT
- Study drug
Visit 4
- BS, VC, CAP
- VA, OCT, FA
- EF
- 24-h BP
- Study drug
Visit 5–13
(months 3–11)
- Ophthalmol.
 Examination
- VA, OCT
- Study drug
Visit 14 + 15
- Ophthalmol.
 Examination
- BS, VC, CAP
- VA, OCT, FA
- EF
- 24-h BP
0
Hoursa
24 4 8 3–11 12
Ranibizumab (n = 11)Group 1
Bevacizumab (n = 12)Group 2
“Dry” AMD (n = 25)Group 3
Weeks Months
b
88 patients screened
aUnusable data of flow-mediated dilation
38 patients excluded:
 Not meeting inclusion criteria
 (n = 5)
 Declined study participation
 (n = 33)
Follow-up after 2 and 12 months
Lost to follow-up: n = 7
Died: n = 0
Completed 12-month follow-up
n = 18
Control: n = 25
Patients with non-neovascular AMD
serving as controls
n = 26
Exclusion after allocation: n = 1a
Follow-up after 2 and 12 months
Lost to follow-up: n = 2
Died: n = 1
Completed 12-month follow-up
n = 20
VEGF antagonist: n = 25
Immediate follow-up (24 h)
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Patients with neovascular AMD
allocated to VEGF antagonist
n = 24
Exclusion after allocation: n = 1a
 Fig. 1.  a Treatment schedule. 24-h BP, 24-h 
ambulatory blood pressure monitoring; 
BS, blood sample; VC, vascular compli-
ance; CAP, central aortic pressure; EF, en-
dothelial function assessed by flow-medi-
ated dilatation; FA, fluorescein angiogra-
phy; OCT, optical coherence tomography; 
VA, visual acuity.  b CONSORT flow dia-
gram of all patients included in the SAVE-
AMD Trial. 
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administered (visit 3, day 28 ± 2). On visit 4 (day 56 ± 2) and visit 
14 (week 52 ± 1), vascular compliance, EF, and 24-h blood pressure 
monitoring were performed, and blood was sampled for systemic 
analyses ( Fig. 1 a). On visits 4–13 ophthalmological examinations 
were performed, and ranibizumab/bevacizumab was administered 
depending on the results of the aforementioned examinations us-
ing strict PRN retreatment criteria according to the 2nd year of the 
PrONTO study  [19] .
 Patients were advised not to take any drugs (regular medica-
tion) on the day of cardiovascular examination, especially no 
β-blocker, calcium antagonist, or angiotensin-converting enzyme 
inhibitor. All examinations and measurements were performed in 
the morning. The medical therapy was not changed throughout 
the study. All patients with wet AMD receiving intravitreal anti-
VEGF therapy received routine 4-weekly ophthalmological fol-
low-up including BCVA, complete ophthalmological examina-
tion, and OCT. All patients with dry AMD had a routine ophthal-
mological follow-up at baseline and on weeks 8 and 52 including 
assessment of visual acuity, complete ophthalmic examination, 
and OCT. The trial was conducted in compliance with the proto-
col, guidelines for good clinical practice, and the applicable regu-
latory requirements. The local ethics committee (EK-No. 770) and 
Swissmedic approved the study. All participants gave written in-
formed consent, and the trial was registered at ClinicalTrials.gov 
(Identifier: NCT00727753).
 Endothelium-Dependent and -Independent Vasodilatation 
 FMD was performed according to the current guidelines  [20] 
and as previously described  [21] . Briefly, a B-mode high-resolu-
tion ultrasound scan of the left brachial artery was obtained by 
highly trained and experienced sonographers in a longitudinal sec-
tion between 2 and 10 cm above the elbow, using a high-resolution 
10-MHz linear array transducer and a high-resolution ultrasound 
system (Siemens X300; Siemens Switzerland AG, Zurich, Switzer-
land). The analogue video signal was acquired with a video pro-
cessing system that computed the artery diameter in real-time 
(FMD Studio  [22] , a system for real-time measurement; Institute 
of Clinical Physiology, Pisa, Italy). The high reproducibility of the 
method has been demonstrated recently  [23, 24] . Baseline vessel 
size was considered as the mean of the measures obtained during 
the 1st min. FMD was calculated as the maximal percent increase 
in diameter above baseline. A reduction in FMD is regarded as EF 
worsening. Endothelium-independent dilatation was measured 
after sublingual glycerol trinitrate (GTN; 0.4 mg, Nitrolingual 
spray; Pohl-Boskamp, Hohenlockstedt, Germany) application by 
recording arterial diameter continuously for at least 6 min. The 
response to GTN was calculated as the maximum percent increase 
in vessel size above baseline.
 Special Laboratory Analyses 
 Oxidative Stress Marker 
 8-Epi-PGF 2α (15-F 2t -isoprostane) was measured in the plasma 
with an 8-isoprostane enzyme immunoassay (8-Isoprostane Ex-
press EIA Kit; Cayman Chemicals, Ann Arbor, MI, USA; intra-
assay coefficient of variation, CV, 7.2%, interassay CV 15.5%).
 Prostaglandins and Thromboxane 
 Prostaglandin E 2 (PGE 2 ) was measured in plasma using the 
PGE 2 EIA Kit – monoclonal (Cayman Chemicals; intra-assay CV 
3.7%, interassay CV 11.6%). Thromboxane B 2 (TBXB 2 ) was deter-
mined in plasma using the TBXB 2 EIA Kit (Cayman Chemicals; 
intra-assay CV 19.9%, interassay CV 24.3%).
 Vascular Endothelial Growth Factor 
 VEGF concentration in plasma samples was determined using 
the Quantikine Human VEGF Immunoassay, a sandwich ELISA 
system provided by R & D Systems (Abingdon, UK). ELISA was 
performed precisely according to the provider’s recommenda-
tions. The minimal detectable dose is typically <9.0 pg/mL accord-
ing to the manufacturer.
 Ambulatory Blood Pressure Measurement 
 Ambulatory blood pressure was assessed over 24 h using the 
Tracker NIBP 2 (Delmar ® ; Del Mar Reynolds Medical, Hertford, 
UK) before and after the treatment phase according to current 
guidelines  [25] . Patients were asked to keep their arm calm while 
the cuff was inflating and to avoid excessive physical activity dur-
ing monitoring. The monitors were programmed to take readings 
every 15 min during daytime and every 30 min during nighttime.
 Vascular Compliance 
 Arterial stiffness was determined by assessment of pulse wave 
velocity (PWV) and augmentation index (AIX) with the Sphygmo-
Cor applanation tonometer system (AtCor Medical Inc, Itasca, IL, 
USA) according to established protocols  [26, 27] . PWV was mea-
sured between the carotid and femoral artery according to the re-
cent guidelines for assessment of arterial compliance  [28] . Patients 
rest in the supine position for 15 min; measurements were taken 
immediately after recording of brachial blood pressure. AIX was 
assessed at the level of the brachial artery by obtaining 10 high-
quality PWV measurements with automatic calculation of AIX us-
ing the manufacturer’s proprietary software after normalization of 
heart rate to 75 bpm. Carotid-femoral PWV was calculated by di-
viding the distance to the distal site by the pressure wave transit 
time. Transit time between arterial sites was determined in relation 
to the R wave of the electrocardiogram (ECG). The surface dis-
tance from the suprasternal notch to the distal (femoral) recording 
site was measured, and the pressure wave transit time was calcu-
lated using a foot-of-the-wave to foot-of-the-wave method. A sin-
gle high-fidelity applanation tonometer (Millar, Houston, TX, 
USA) was used to obtain a proximal and a distal pulse recorded 
sequentially a short time apart. Then transit time was obtained by 
subtraction from the delays between ECG and both pulses.
 Shear Stress-Dependent Platelet Function 
 Shear stress-dependent platelet function was assessed with a 
cone and platelet analyzer as described previously  [21] .
 Ophthalmological Methods 
 Methods used for ophthalmic evaluation included BCVA using 
the retro-illuminated, standardized charts (Precision vision, La 
Salle, IL, USA) of the Early Treatment Diabetic Retinopathy Study 
(ETDRS) at 4 m, FA of the retina performed with the Heidelberg 
Retina Angiograph II (Heidelberg Engineering, Heidelberg, Ger-
many) and the Spectralis spectral domain OCT system (Heidel-
berg Engineering) for transsectional analysis of the retina. The au-
tomated segmentation software of the Spectralis system was used 
for calculation of the central retinal thickness (CRT). All three 
evaluations were performed according to standardized protocols 
established for clinical trials.
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 All patients with the neovascular form of AMD obtained intra-
vitreal injections of either ranibizumab (Lucentis ® ; Novartis AG, 
 Basel, Switzerland) or bevacizumab (Avastin ® ; Hoffmann La Roche 
AG, Basel, Switzerland). Bevacizumab was compounded into sterile, 
prefilled syringes by the Swissmedic-certified pharmacy at the City 
Hospital Triemli Zurich using isolators (ENVAIR; Haslingden, Ros-
sendale, UK). All intravitreal injections were performed according 
to a standardized procedure including preinjection of topical anes-
thetics and 5% povidone iodine, as well as the injection of 0.5 mg 
ranibizumab (0.05 mL) or 1.25 mg bevacizumab (0.05 mL) into the 
vitreous cavity under sterile conditions in a fully equipped operating 
room including laminar airflow in the operating field. Details of the 
injection procedure are described in a recent publication  [29] . 
 Statistical Analysis 
 The treatment effect of the VEGF antagonists ranibizumab or 
bevacizumab was compared to no treatment (dry AMD). Further-
more, EF differences before and after treatment were analyzed. 
Power calculation was based upon the results of the study protocol 
reported by Chenevard et al.  [30] . The primary endpoint was de-
fined as difference in FMD between baseline and after 8 weeks of 
treatment with a VEGF antagonist. Based on previous experience 
 [30] , we hypothesized a difference in the (mean) FMD of 1.3 ± 1.5% 
between baseline and 8 weeks. Using an α error level of 0.05, 25 pa-
tients per treatment group were needed to reach a statistical power 
of 0.8. Descriptive data are given as means ± SD. For statistical 
analyses, patients receiving ranibizumab or bevacizumab were both 
analyzed for the primary endpoint as per protocol, and data of both 
treatment groups were pooled in the group “VEGF antagonist” 
treatment (no difference in prespecified cardiovascular endpoints 
between patients receiving bevacizumab and ranibizumab) and 
compared to dry AMD. Within-group differences of outcome vari-
ables (FMD and secondary outcome variables) were examined by 
the Wilcoxon signed-rank test. Between-group differences were 
calculated using the Mann-Whitney U test. Calculations were per-
formed using SPSS 20.0 for Mac (SPSS Inc., Chicago, IL, USA).
 Results 
 Study Population 
 Of 88 patients screened ( Fig. 1 b), 24 patients with wet 
AMD were randomized to ranibizumab or bevacizumab, 
and 26 patients with dry AMD were included in the con-
trol group. In each of these groups, 1 patient was exclud-
ed due to unusable data of the FMD measurements 
( Fig. 1 b). At baseline, patient characteristics and labora-
tory parameters, with the exception of serum albumin 
levels, which were lower in patients with dry than wet 
AMD, did not differ between groups ( Tables 1 ,  2 ).
 Importantly, due to thromboembolic events occurring 
in 3 patients, the events were reviewed by an independent 
data safety monitoring board (Chair: Prof. Ferenc Follath, 
MD). All thromboembolic events (1 fatal stroke, 1 pul-
monary embolism, and 1 suspected transient ischemic at-
tack) occurred in patients receiving VEGF inhibitors. Al-
though the data safety monitoring board could neither 
prove nor exclude a causal relationship with the respec-
tive study drugs, the investigators independently took 
the decision to stop the study. Ultimately, a total of 38 
patients completed the 12-month follow-up: 20 patients 
with wet and 18 patients with dry AMD.
 Effects of VEGF Inhibitors on Cardiovascular 
Parameters 
 Treatment with VEGF inhibitors did not significantly 
change FMD (from 4.7 ± 2.4 to 3.9 ± 1.9%,  p = 0.07, base-
line vs. 8 weeks, and to 5.1 ± 2.0%;  p = 0.93 baseline vs. 
after 1 year;  Fig. 2 a). FMD was lower in the control group 
(6 ± 3.9 vs. 5.1 ± 2.2%;  p = 0.03) after 8 weeks as well as 
after 1 year (4.6 ± 2.8%,  p = 0.01 vs. baseline;  Fig. 2 a). En-
dothelium-independent dilatation induced by GTN re-
mained unchanged before and after treatment with VEGF 
inhibitors (baseline vs. 2 months:  p = 0.44, baseline vs. 12 
months:  p = 0.52), as well as in the control group (baseline 
vs. 2 months:  p = 0.81, baseline vs. 12 months:  p = 0.41). 
No differences in FMD were found between patients re-
ceiving ranibizumab and patients receiving bevacizumab 
(ranibizumab vs. bevacizumab:  p = 0.94 after 2 months 
 Table 1. Patient characteristics and concomitant medication
Neovascular 
AMD treated 
with VEGF 
inhibitors
Control 
(dry AMD)
p
value
Patients, n 23 25
Females 12 (52%) 15 (60%)
Age, years 76.5 ± 6.7 74.8 ± 6.7 0.32
Body weight, kg 74.2 ± 12.6 70.1 ± 15.8 0.30
Heart rate, bpm 64 ±13 64 ± 9 0.54
Blood pressure, mm Hg
Systolic 130 ± 12 127 ± 14 0.18
Diastolic 74 ± 7 74 ± 8 0.69
Concomitant medication, n (%)
Aspirin 5 (22) 7 (28)
Clopidogrel 0 (0) 1 (4)
Vitamin K antagonist 1 (4) 1 (4)
Statins 6 (26) 6 (24)
ACEI/AR 6 (26) 10 (40)
β-Blockers 7 (30) 6 (24)
Diuretics 4 (17) 8 (32)
Calcium antagonists 2 (9) 4 (16)
NSAIDs 6 (26.1) 1 (4)
 ACEI, angiotensin-converting enzyme inhibitor; ARB, angio-
tensin receptor blocker; NSAIDs, non-steroidal anti-inflammato-
ry drugs. 
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and  p = 0.53 after 12 months). Due to the neutral primary 
endpoint, no further adjustment by center was performed. 
At baseline, there was no difference in heart rate, blood 
pressure, and PWV between patients treated with VEGF 
inhibitors and the control group ( Table  3 ). During the 
course of the study, diastolic ambulatory blood pressure 
dropped from 74 ± 7 mm Hg at baseline to 72 ± 6 mm Hg 
after 12 months ( p = 0.03) and AIX increased from 30.4 ± 
7.2 at baseline to 36.5 ± 9.3 after 12 months ( p = 0.02) in 
the patients treated with VEGF inhibitors only ( Fig. 2 b; 
 Table  3 ). Endothelium-dependent or -independent vas-
cular function, as well as PWV and AIX, did not change 
24 h after the first injection of VEGF antagonists ( Table 4 ). 
 Effects of VEGF Inhibitors on Ophthalmological 
Parameters 
 At the 2- and 12-month follow-ups, the ophthalmo-
logical parameters BCVA and CRT were evaluated as sec-
ondary outcomes. At baseline, mean BCVA was 59.2 
 ETDRS letters (20/63 –1 ) in the eyes with neovascular 
AMD and 69.5 ETDRS letters (20/40 +1 ) in all eyes with 
dry AMD of the control group. Under treatment with in-
Baselinea
20
FM
D,
 %
15
10
5
0
2 months 12 months
p = 0.32
p = 0.07
p = 0.03
p = 0.93
p = 0.01
p = 0.11 p = 0.23
Baselineb
80
AI
X,
 %
60
40
20
0
2 months 12 months
p < 0.0001
p = 0.21
p = 0.06
p = 0.02
p = 0.51
p = 0.05 p = 0.24
? VEGF antagonist (n = 23)
? Control (n = 25)
 Fig. 2.  a Endothelium-dependent vasodilatation in patients with 
anti-VEGF treatment versus control group. FMD, flow-mediated 
dilatation. The VEGF antagonist group comprised 23 patients (the 
12-month follow-up was completed by 20 patients; a thromboem-
bolic event occurred in 3 of these patients) and the control group 
(AMD) comprised 25 patients (the 12-month follow up was com-
pleted by 18 patients).  b Augmentation index (AIX) in patients 
with anti-VEGF treatment vs. control group. The VEGF antago-
nist group comprised 23 patients (the 12-month follow-up was 
completed by 20 patients; a thromboembolic event occurred in 3 
of these patients) and the control group (AMD) comprised 25 pa-
tients (the 12-month follow-up was completed by 18 patients). 
 Table 2. Laboratory parameters at baseline in both treatment 
groups
VEGF 
antagonist
Control 
(dry AMD)
p 
value
Patients, n 23 25
Hemoglobin, g/dL 14.6 ± 1.4 14.4 ± 1.3 0.64
Hematocrit. % 43 ± 3.9 42.7 ± 3.7 0.83
Erythrocytes, ×106/μL 4.8 ± 0.5 4.8 ± 0.5 0.64
MCV, fL 89.1 ± 3.5 89.3 ± 3.9 0.93
MCH, pg 30.3 ± 1.4 30.1 ± 1.8 0.55
MCHC, g/dL 34 ± 1 33.7 ± 1.4 0.64
Platelets, ×10³/μL 267 ± 46 258 ± 71 0.4
Leukocytes, ×10³/μL 6.5 ± 1.6 6.1 ± 1.8 0.34
Lymphocytes, ×10³/μL 1.6 ± 0.5 1.5 ± 0.5 0.32
Sodium, mmol/L 141 ± 3 141 ± 3 0.99
Potassium, mmol/L 3.8 ± 0.4 3.9 ± 0.3 0.51
Magnesium, mmol/L 0.9 ± 0.1 0.9 ± 0.1 0.99
Phosphate, mmol/L 0.9 ± 0.1 0.9 ± 0.1 0.99
Creatinine, μmol/L 83.3 ± 15.7 81.3 ± 16.7 0.51
Albumin, g/L 44.4 ± 2.2 42.5 ± 3 0.01
AST, U/L 27.4 ± 5.3 26.6 ± 5.3 0.56
ALT, U/L 23.1 ± 8.6 20.7 ± 8.3 0.2
Alkaline phosphatase, U/L 69.2 ± 14 62.7 ± 11.1 0.09
C-reactive protein, mg/L 4.6 ± 5.5 5.2 ± 12.1 0.84
Glucose, mmol/L 5.6 ± 0.5 5.4 ± 0.6 0.1
Total cholesterol, mmol/L 5.4 ± 0.9 5.8 ± 0.7 0.28
HDL cholesterol, mmol/L 1.5 ± 0.5 1.8 ± 0.4 0.34
LDL cholesterol, mmol/L 3.3 ± 0.8 3.4 ± 0.7 0.61
Triglycerides, mmol/L 1.3 ± 0.4 1.3 ± 0.5 0.74
Thromboxane B2, pg/mL 29.3 ± 4.4 27.8 ± 5.3 0.52
Prostaglandin E2, pg/mL 20.8 ± 10.1 24.2 ± 6 0.3
15-F2t-isoprostane, pg/mL 73.4 ± 39.7 78.4 ± 28.7 0.25
VEGF, pg/mL 76.6 ± 57.1 n/a n/a
Means ± SD. MCV, mean corpuscular volume; MCH, mean 
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin 
concentration; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; HDL, high-density lipoprotein; LDL, low-
density lipoprotein; VEGF, vascular endothelial growth factor. 
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travitreal anti-VEGF therapy, the eyes with neovascular 
AMD improved nonsignificantly by a mean of 2.8 letters 
( p = 0.34) and 4.2 letters ( p = 0.12) at the 2- and 12-month 
follow-ups. No significant difference was detected be-
tween eyes treated with ranibizumab or bevacizumab. 
The eyes with dry AMD in the control group showed a 
mild vision improvement of 0.1 and 0.5 ETDRS letters at 
the 8- and 52-week follow-ups, respectively. Mean CRT 
measured by OCT decreased significantly in the group 
treated with intravitreal anti-VEGF therapy from 401.5 
μm at baseline to 285.0 μm ( p < 0.001) and 313 μm ( p = 
0.002) at 8 and 52 weeks. No significant difference was 
observed between both drugs. CRT remained unchanged 
in the eyes with dry AMD in the control group. CRT was 
295.1 μm at baseline, 291.9 μm at 8 weeks, and 285.4 μm 
at 52 weeks. A mean of 7.5 intravitreal anti-VEGF injec-
tions was performed during follow-up. None of the treat-
ed eyes had a serious ocular adverse event (e.g., endo-
phthalmitis, retinal detachment, and lens damage).
 Effects of VEGF Inhibitors on Special Laboratory 
Parameters 
 VEGF plasma levels were measured in the VEGF 
 inhibitor group only. VEGF plasma levels did not 
change significantly from 76.6 ± 57.1 pg/mL at baseline 
to 60.4 ± 31.9 pg/mL after 24 h ( p = 0.22 vs. baseline) and 
to 80.8 ± 78.3 pg/mL after 8 weeks ( p = 0.68 vs. baseline) 
during 4-weekly treatment with VEGF inhibitors. All 3 
patients with thromboembolic events obtained anti-
VEGF treatment. At baseline, no difference was detected 
between the study groups regarding TBXB 2 , PGE 2 , and 
15-F 2t -isoprostane ( Table 2 ). While levels of PGE 2 and 
15-F 2t -isoprostane did not change throughout the study 
period ( Fig. 3 a, c), TBXB 2 was significantly reduced after 
8 weeks in the control group compared to the VEGF in-
hibitor group ( p = 0.04;  Fig. 3 b). Platelet adhesion as well 
as platelet size did not change in either group over time 
( Fig. 3 d, e).
 Table 3. Differences in body weight, heart rate, systolic/diastolic ambulatory blood pressure (BP), pulse wave velocity (PWV), and 
augmentation index (AIX) between patients with neovascular age-related macular degeneration (AMD) receiving a VEGF antagonist 
versus patients with non-neovascular AMD (controls)
Anti-VEGF patients (n = 23) p 
valuea
p 
valueb
 Controls (n = 25) p 
valuea
p 
valuebbaseline 2 mo. 12 mo. ba seline 2 mo. 12 mo.
Heart rate, bpm 64 ± 13 62 ± 11 61 ± 9 0.69 0.1 64 ± 9 64 ± 7 64 ± 8 0.67 0.5
Systolic BP, mm Hg 130 ± 12 128 ± 10 129 ± 14 0.29 0.78 127 ± 14 122 ± 12 123 ± 11 0.08 0.6
Diastolic BP, mm Hg 74 ± 7 72 ± 7 72 ± 6 0.07 0.03 74 ± 8 73 ± 8 72 ± 8 0.35 0.13
PWV, ms–1 9.2 ± 2.7 9.1 ± 2.7 8.7 ± 2.7 0.61 0.4 8.7 ± 2.4 8.8 ± 2.3 8.3 ± 1.8 0.7 0.63
AIX, % 30.4 ± 7.2 31.9 ± 9 36.5 ± 9.3 0.21 0.02 40.3 ± 8.3 37.8 ± 6.6 40.1 ± 9 0.06 0.51
In the group treated with VEGF antagonist, 20 patients completed the 12-month follow-up, and in the control group, 18 patients. 
a  Baseline vs. 2 months. b Baseline vs. 12 months.
 Table 4. Differences in flow-mediated dilatation (FMD), glycerol trinitrate-mediated dilatation (GTN), pulse wave velocity (PWV), and 
augmentation index (AIX) in patients with neovascular age-related macular degeneration receiving a VEGF antagonist (ranibizumab 
or bevacizumab)
FMD, % p
value
GTN, % p
value
PWV, ms–1 p
value
AIX, % p
valuebaseline 24 h baseline 24 h baseline 24 h baseline 24 h
Ranibizumab, 
n = 11 4.7 ± 3.5 3.5 ± 2.7 0.14 13.8 ± 4.9 14.2 ± 7.3 0.68 10.5 ± 3.3 9.7 ± 3.6 0.18 32.3 ± 6.4 30.2 ± 9.6 0.34
Bevacizumab, 
n = 12 4.5 ± 1.8 4.8 ± 1.9 0.31 13.3 ± 3.8 12.1 ± 4 0.36 7.7 ± 1.7 8.4 ± 2.1 0.48 27.6 ± 3.2 29.9 ± 5.9 0.07
Means ± SD.
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 Discussion 
 The SAVE-AMD trial shows for the first time that 
acute and long-term treatment up to 1 year with the 
VEGF inhibitors ranibizumab or bevacizumab in patients 
with neovascular AMD does not impair EF, platelet 
 function, or blood pressure compared to patients with 
“dry” AMD.
 VEGF plays an important role in the promotion of 
CNV and vessel leakage that leads to loss of central vision 
in AMD  [31] . Anti-VEGF therapy improves vision and 
quality of life in a large number of patients suffering from 
neovascular “wet” AMD  [10, 31] . In 2006, 2 phase III clin-
ical trials with ranibizumab showed that monthly intra-
vitreal injections prevented vision loss and improved vi-
sual acuity of patients with neovascular AMD  [1, 32] . 
While intravenous bevacizumab was approved by the FDA 
for patients with metastatic colorectal cancer in February 
2004, the intravitreal use of bevacizumab to treat neovas-
cular AMD has become a common off-label use worldwide 
due to significantly lower costs compared to ranibizumab. 
Recently, multiple controlled clinical trials comparing 
bevacizumab and ranibizumab have shown similar func-
tional results in patients with neovascular AMD  [6–9] .
 EF plays a pivotal role in the pathogenesis and clinical 
course of atherosclerosis and independently predicts ad-
verse cardiovascular events  [14] . In this context, any ben-
eficial effects of anti-VEGF therapies in the eye must be 
weighed against potential systemic adverse effects of these 
agents. This is particularly important when potent “pan”-
anti-VEGF therapies, such as ranibizumab and bevaci-
zumab, may exert systemic extra-ocular side effects by 
 preventing potentially cardioprotective systemic effects of 
VEGF  [31] . As the majority of patients with wet AMD is 
of advanced age and at increased risk of cardiovascular 
events, the need to assess cardiovascular safety of these po-
tent drugs is warranted. These findings are of great clinical 
relevance as large-scale clinical trials specifically address-
ing the cardiovascular safety of these drugs are lacking.
 Repeated injections of anti-VEGF medications can 
cross the blood-retinal barrier, and the agents may enter 
the systemic circulation, thereby decreasing systemic 
VEGF serum concentrations  [12, 13] . First, although the 
drug is administered by injection through the sclera into 
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 Fig. 3. Plasma levels of prostaglandin E 2 (PGE 2 ;  a ), thromboxane B 2 (TBXB 2 ;  b ), 15-F 2t -isoprostane (8-IP;  c ), 
platelet adhesion ( d ), and platelet size ( e ) at baseline and after treatment with anti-VEGF treatment versus 
control group. 
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the vitreous cavity, systemic absorption may induce sys-
temic adverse effects (mean peak serum concentration af-
ter intravitreal injection: ranibizumab 1.5 ng/mL, plasma 
half-life: 12 h; bevacizumab 3,300 ng/mL, plasma half-
life: 21 days)  [13] . Second, because anti-VEGF treatment 
is potentially required for years, chronic VEGF inhibition 
may cause side effects that are not immediately apparent. 
Therefore, VEGF antagonists may be a double-edged 
sword. While key in the pathogenesis of AMD, VEGF 
plays at the same time a pivotal role in maintaining sys-
temic vascular integrity, particularly under conditions of 
ischemia and hypoxia. Indeed, VEGF is an essential ele-
ment required for reperfusion in myocardial infarction 
 [33] as well as in cerebral ischemia  [16, 34] . Moreover, 
intramyocardial injection of the VEGF 121 isoform ame-
liorates myocardial ischemia and reduces angina in 
 patients with coronary artery disease  [35] . Anti-VEGF 
agents elicit changes both in the normal and pathological 
microvasculature, with fenestrated vessels in particular 
exhibiting sensitivity to VEGF withdrawal  [36, 37] . While 
2 studies reported decreased VEGF levels following intra-
vitreal injection of bevacizumab or ranibizumab  [38, 39] , 
we did not find any differences in VEGF levels before and 
after treatment with VEGF inhibitors.
 Previous randomized clinical trials comparing ranibi-
zumab or bevacizumab reported very low cardiovascular 
event rates, and as none of these trials had been designed 
to specifically address cardiovascular safety, a vascular 
risk associated with these drugs could not be excluded  [1, 
40, 41] . Intriguingly, the recently published IVAN  [42] 
and CATT  [43] trials comparing ranibizumab and beva-
cizumab in >1,500 patients with neovascular AMD dem-
onstrated a significantly increased death rate and a trend 
to more Antiplatelet Trialists’ Collaboration  [44] (APTC) 
events in the treatment arms with  fewer treatments (PRN 
treatment). Interestingly, in the IVAN study, a more pro-
nounced reduction in systemic VEGF levels in eyes treat-
ed with bevacizumab compared to ranibizumab and an 
increased systemic VEGF reduction in frequently versus 
less frequently  ( PRN ) treated patients was shown. While 
this finding may be explained in part by the longer half-
life of bevacizumab compared with the smaller Fab frag-
ment ranibizumab, no correlation between systemic ad-
verse events in the study and reduced systemic VEGF 
 levels were found  [45] . The absence of evidence for a 
worsening in EF in one vascular bed in AMD patients 
repeatedly treated with anti-VEGF does not exclude that 
continuous, monthly intravitreal anti-VEGF over pro-
longed periods of time has no impact on other vascular 
beds. In addition, only one systemic vascular bed was 
evaluated in this study and analysis of cerebral vascula-
ture, for example, might still show impaired NO-depen-
dent EF. Moreover, other NO-unrelated mechanisms 
may underlie increased rates of thromboembolic events 
following repeated anti-VEGF treatment observed in this 
study. Importantly, as VEGF also affects platelet function 
via the NO pathway  [46] , VEGF antagonism may exert 
prothrombotic effects, as suggested by the increased rate 
of such events in the AMD group.
 In line with this interpretation, intravenous use of 
 bevacizumab in cancer patients may have serious system-
ic complications, including an increased risk of thrombo-
embolic events, hypertension, hemorrhage, proteinuria, 
impaired wound healing, and gastro-intestinal perfora-
tion  [47] . However, whether these systemic complications 
are relevant to AMD patients receiving very low doses by 
intravitreal injection remains to be determined. Early ap-
proval studies with ranibizumab (comparing its effects to 
placebo or photodynamic therapy) were not designed to 
assess clinically relevant thromboembolic events. As the 
latter trials established substantial beneficial effects of in-
traocular anti-VEGF application on CNV and visual acu-
ity, a comparison to placebo became obsolete in all subse-
quent randomized controlled trials  [7, 47, 48] .
 Patients with AMD tend to be older and have an in-
creased prevalence of cardiovascular risk factors such as 
hypertension and diabetes leading to myocardial infarc-
tion or stroke  [31, 49, 50] . Indeed, the cardio- and cere-
brovascular safety of anti-VEGF therapies was further 
questioned by reports of an increased incidence of cere-
brovascular events in patients treated with ranibizumab, 
including more and fatal or nonfatal myocardial infarc-
tions compared to control subjects  [51, 52] . At first sight, 
these findings are in line with our study, which was ter-
minated because 3 of the 56 patients included in the study 
experienced thromboembolic events, all of which oc-
curred in patients treated with VEGF inhibitors. How-
ever, our study was not powered to evaluate thromboem-
bolic events, and the 3 incidences could be due to chance 
alone in an aged population. Moreover, the cardiovascu-
lar risk profile of patients with dry AMD may differ from 
patients with wet AMD. Meta-analyses, combining the 
data from various randomized controlled trials, yielded 
an overall low thromboembolic event rate  [16] . In addi-
tion, a recent retrospective cohort analysis of United 
States Medicare beneficiaries with AMD did not show an 
increased risk for acute myocardial infraction, stroke, or 
all-cause mortality comparing study cohorts prior and af-
ter the introduction of anti-VEGF agents as standard of 
care for neovascular AMD in 2006  [53] .
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
17
9 
- 9
/1
2/
20
17
 6
:4
4:
47
 P
M
 Enseleit   et al.
 
Ophthalmologica
DOI: 10.1159/000478665
10
 The SAVE-AMD study was stopped due to safety con-
cerns, and, therefore, limited the power of the secondary 
ophthalmological outcomes. BCVA improved in the 
group with neovascular AMD treated with either ranibi-
zumab or bevacizumab similar to other large prospective 
clinical trials comparing both drugs  [2, 8, 42] . Although 
improvement in BCVA was not statistically significant, 
treatment with VEGF antagonists improved visual acuity 
and reduced CRT comparably to results shown by large 
randomized clinical trials  [41–43] . It is reassuring that 
CRT was reduced due to the antivascular leakage effects 
of both drugs resembling the outcomes of other anti-
VEGF studies in neovascular AMD  [2, 8, 42] . In contrast, 
the control group consisting of dry AMD eyes demon-
strated no relevant functional or anatomic change within 
a 1-year follow-up.
 Conclusions 
 SAVE-AMD, the first prospective evaluation of the 
acute and long-term cardiovascular safety of VEGF in-
hibitors, did not demonstrate a change in EF, vascular 
compliance, or platelet function. While the study was not 
powered to assess morbidity and mortality, 3 serious car-
diovascular events, all of which occurred in patients treat-
ed with VEGF antagonists, may indicate a potential safe-
ty hazard. In this context, further interdisciplinary studies 
are warranted.
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